In cardiac arrest resuscitation pharmacology, epinephrine acts as a non-selective adrenergic agonist that increases systemic vascular resistance to preferentially preserve cardiac and cerebral perfusion, while amiodarone functions as a class III anti-arrhythmic used for shock-refractory ventricular fibrillation/tachycardia. Both drugs demonstrate evidence of improved short-term outcomes (return of spontaneous circulation, survival to hospital admission) but lack robust evidence for improving long-term survival to hospital discharge, illustrating the distinction between short-term physiological benefit and long-term outcome efficacy in resuscitation pharmacology. This reflects the broader domain of emergency/critical care pharmacotherapy, where mechanism-based rationale for an intervention does not always translate into demonstrated mortality benefit.
In cardiac arrest resuscitation pharmacology, epinephrine acts as a non-selective adrenergic agonist that increases systemic vascular resistance to preferentially preserve cardiac and cerebral perfus…